AbbVie Inc. buy tamam
Start price
15.06.17
/
50%
€63.34
Target price
04.11.21
€126.73
Performance (%)
59.30%
End price
05.11.21
€100.90
Summary
This prediction ended on 05.11.21 with a price of €100.90. With a performance of 59.30% the BUY prediction by tamam was a big success. A total of €17.34 was paid as dividends for this prediction. tamam has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| AbbVie Inc. | 3.529% | 3.529% | 7.172% | 71.987% |
| iShares Core DAX® | 2.112% | -0.367% | 13.466% | 16.854% |
| iShares Nasdaq 100 | -2.197% | -3.794% | 38.426% | 42.934% |
| iShares Nikkei 225® | -1.555% | -7.320% | 18.451% | 2.941% |
| iShares S&P 500 | -0.472% | -2.078% | 27.488% | 41.955% |
Comments by tamam for this prediction
In the thread AbbVie Inc. diskutieren
tamam stimmt der Outperform-Einschätzung der institutionellen Analysten zu
tamam stimmt am 15.06.2017 der Outperform-Einschätzung der institutionellen Analysten zu.
In the thread Trading AbbVie Inc.
Die von tamam gewählte maximale Laufzeit wurde überschritten